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SUMMARY
Activation of NF-κB, pivotal for immunity and oncogenesis, is tightly controlled by multiple
feedback mechanisms. In response to DNA damage, SUMOylation of NEMO (NF-κB essential
modulator) is critical for NF-κB activation, however SUMO proteases and feedback mechanisms
involved remain unknown. Here we show that among the six known SENPs (Sentrin/SUMO-
specific proteases) only SENP2 can efficiently associate with NEMO, deSUMOylate NEMO and
inhibit NF-κB activation induced by DNA damage. We further show that NF-κB induces SENP2
(and SENP1) transcription selectively in response to genotoxic stimuli, which involves ATM
(ataxia telangiectasia mutated)-dependent histone methylation of SENP2 promoter κB regions and
NF-κB recruitment. SENP2-null cells display biphasic NEMO SUMOylation and activation of
IKK and NF-κB, and higher resistance to DNA damage-induced cell death. Our study establishes
a self-attenuating feedback mechanism selective to DNA damage induced signaling to limit NF-
κB-dependent cell survival responses.
INTRODUCTION
The transcription factor NF-κB is activated by multiple extracellular signals and intracellular
stress conditions to control diverse functions, including innate and adaptive immunity and
cell death responses (Hayden and Ghosh, 2008; Perkins, 2007). Inactive NF-κB exists in the
cytoplasm in association with an inhibitor protein, such as IκBα. Canonical activation of
NF-κB requires signaling events that activate IκB kinase (IKK) complexes, composed of
catalytic subunits (IKKα/IKK1 and IKKβ/IKK2) and a regulatory subunit IKKγ/NEMO
(NF-κB essential modulator). Tight control of NF-κB activity is critical for normal
physiology; for example, insufficient activity contributes to the loss of cells in
neurodegenerative diseases whereas chronic activity promotes autoimmunity and
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Negative feedback regulation plays an important role in the control of NF-κB activity
(Renner and Schmitz, 2009). A classical example is NF-κB-dependent induction of IκBα
synthesis following cell stimulation, which directly antagonizes NF-κB (Chiao et al., 1994;
Sun et al., 1993). Cells deficient in IκBα show higher basal and more sustained signal-
inducible NF-κB activities (Beg et al., 1995). More recent studies have provided examples
of feedback regulation acting at or upstream of the IKK activation step. For example, during
signaling induced by tumor necrosis factor α (TNFα), receptor interacting protein 1 (RIP1)
becomes modified byK63-linked polyubiquitin chains (Liu and Chen, 2011). These
ubiquitin chains are thought to function as a signaling scaffold where ubiquitin-binding
proteins assemble to induce activation of IKK and NF-κB. Expression of deubiquitinases
(DUBs), including A20 and CYLD (cylindromatosis), are also induced by TNFα stimulation
in an NF-κB-dependent fashion. These DUBs then remove polyubiquitin chains to limit IKK
activation (Brummelkamp et al., 2003; Jono et al., 2004; Kovalenko et al., 2003; Lee et al.,
2000; Sun, 2010; Trompouki et al., 2003; Wertz et al., 2004). Consequently, a deficiency in
A20 or CYLD can lead to augmented and sustained NF-κB activity in response to
inflammatory stimuli and contribute to inflammatory disorders as well as oncogenesis,
Transcriptional regulation of target genes by NF-κB is complex with specificity and
temporal regulation driven by κB sites, cell types, specific signals, and others (Hoffmann et
al., 2006; Natoli, 2010). In a striking example, one nucleotide substitution in the distal κB
element located on the IP-10 promoter can define signal-specific (TNFα) induction of this
gene in a NF-κB family specific manner (p65 dimers) (Leung et al., 2004). Additionally, the
chromatin structure is recognized to impose a barrier to NF-κB binding and helps establish
the specificity of NF-κB target gene induction. Based on the requirement of prior chromatin
modifications, Natoli and colleagues have categorized NF-κB target genes into two broad
classes, “fast” and “slow”, where fast genes display constitutive and immediate accessibility
of NF-κB association whereas slow genes require a specific chromatin remodeling, such as
histone tail methylation, prior to the access of NF-κB to specific κB binding elements
(Natoli, 2009).
Among the large number of inducing signals, DNA damage in the nucleus can also trigger
activation of NF-κB and represents a unique scenario due to the initiating signal emanating
from the nucleus rather than the plasma membrane (Janssens and Tschopp, 2006; Miyamoto,
2011). We previously found that NF-κB activation by genotoxic stimuli involves
modification of NEMO by SUMO-1 (small ubiquitin-related modifier 1) (Huang et al.,
2003). This SUMOylation seems to occur on IKK-free NEMO and correlates with nuclear
localization of NEMO, association with the DNA damage-activated nuclear kinase ATM
(ataxia telangiectasia mutated), ATM-dependent phosphorylation (Wu et al., 2006), and
subsequent ATM-dependent activation of IKK in the cytoplasm to induce NF-κB activation
(Hinz et al., 2010; Wu et al., 2010). Like ubiquitin, SUMO is typically conjugated to lysine
residues in target proteins by an E1-E2-E3 enzymatic cascade (Gill, 2004; Hay, 2005; Yeh,
2009). One E1 (an AOS1-UBA2 dimer), one E2 (UBC9) and multiple E3s are known to
induce protein SUMOylation (Ulrich, 2005; Yeh, 2009). Our studies have revealed that the
E3, PIASy (protein inhibitor of STAT y, also known as PIAS4/PIASγ), mediates
SUMOylation of NEMO (Mabb et al., 2006). PIDD (p53-induced death domain protein) and
PARP-1 may also participate in the nucleus to promote NEMO SUMOylation (Janssens et
al, 2005; Stilmann et al., 2009).
Like DUBs opposing ubiquitination, members of the SENP (Sentrin/SUMO-specific
protease) family remove SUMO conjugates (Hay, 2007; Yeh, 2009); however, the potential
role of SUMO proteases in regulation of NF-κB signaling remains unknown. It is also
unclear whether NF-κB could regulate the expression of SENPs, similar to certain DUBs, to
negatively regulate NF-κB signaling. Here we addressed these questions and showed that
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SENP2 and SENP1 are major and minor negative regulators, respectively, of NF-κB
signaling induced by genotoxic stimuli. We also revealed that the genes encoding these
SUMO proteases are direct NF-κB targets selectively induced under DNA damage
conditions. Our study reveals a negative feedback mechanism selectively induced by
genotoxic stimuli involving NF-κB-dependent induction of SUMO proteases to limit NF-
κB-dependent cell survival responses, which may have implications in oncogenesis and
cancer progression.
RESULTS
SENP2 Interacts with NEMO and Limits NF-κB Activation by Genotoxic Stimuli
There are six SUMO protease genes (SENP1, 2, 3, 5, 6 and 7; SENP4 does not exist) known
in the human genome (Hay, 2007; Yeh, 2009). To determine if any of these could modulate
NF-κB signaling induced by genotoxic signals, we took three independent approaches. First,
to reveal which of the SENPs had the potential to interact with NEMO, different SENPs
were co-expressed with NEMO in HEK293 cells and their interaction was assessed by co-
immunoprecipitation (co-IP) analysis following treatment with the topoisomerase inhibitor
etoposide (VP16). Of all the SENPs, SENP2 was the most efficient in interacting with
NEMO (Fig. 1A). Second, their impact on NF-κB activation by VP16 was evaluated by
electrophoretic mobility shift assay (EMSA) following overexpression of individual SENPs.
Again, only SENP2 expression significantly inhibited NF-κB activation induced by VP16
(Fig. 1B) with a maximum observable inhibition of ~50% (Fig. 1C), likely due to relatively
high basal SENP2 expression in this cell type (see below). In contrast to the wild type (wt)
version, overexpression of a catalytically inactive cysteine-to-serine SENP2 mutant (c/s)
caused an increase of NF-κB activation (Fig. 1D). Similarly, κB-dependent luciferase
reporter assay also showed significant decrease and increase in NF-κB activation upon
expression of SENP2-wt and -c/s, respectively (Fig. 1E–F, others not shown). This
suggested that the catalytic activity of SENP2 is required to mediate NF-κB inhibition and
that the catalytically inactive mutant might function in a dominant-negative manner. Finally,
the change in NF-κB activation was analyzed upon expression of siRNAs targeting
individual SENPs. SENP2 knockdown caused increased NF-κB activation by VP16 (Fig.
S1A–C, Fig. 1E–F). Knockdown of SENP7 was also associated with an increase in NF-κB
activation by VP16 (Fig. S1A–C) but not by topoisomerase I inhibitor camptothecin (CPT)
or doxorubicin (not shown). In contrast, SENP2 showed functional significance with
different genotoxic stimuli in multiple cell systems (see below). Thus, three independent
experimental approaches suggested SENP2 was the main negative regulator of NF-κB
signaling induced by genotoxic agents.
SENP2 DeSUMOylates NEMO
Since SENP2 is primarily localized in the nucleus (Hang and Dasso, 2002) and
SUMOylation of NEMO is thought to be a nuclear event (Janssens et al., 2005; Mabb et al.,
2006; Stilmann et al., 2009), we next tested whether SENP2 could modulate NEMO
SUMOylation. Overexpression of SENP2-wt decreased the amount of SUMOylated NEMO
induced by VP16 (Fig. 2A). In contrast, SENP2-c/s mutant caused a slight increase in
NEMO SUMOylation, consistent with the observed increase in NF-κB activation (Fig. 1D).
Interaction of endogenous SENP2 and NEMO was induced by VP16 treatment (Fig. 2B).
NEMO deletion analysis indicated that its N-terminal region is required for SENP2
interaction (Fig. 2C). As predicted, the SENP2-c/s mutant interacted with NEMO (Fig.
S2A), which required the central region of SENP2 (Fig. 2D). Finally, SENP2 interacted
more efficiently with a SUMO1-NEMO fusion protein than with NEMO alone (Fig. 2E),
suggesting that addition of the SUMO-1 moiety increased SENP2 interaction.
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We previously showed that the recombinant catalytic domain of SENP1 could
deSUMOylate NEMO in vitro (Mabb et al., 2006). Similarly, a recombinant SENP2
catalytic domain deSUMOylated NEMO in vitro (Fig. S2B). When different amounts of
full-length SENP1 and SENP2 were analyzed in parallel in their abilities to deSUMOylate
NEMO in vitro, SENP2 was found to be more proficient than SENP1 (Fig. 2F), correlating
with the ability of SENP2 but not SENP1 to efficiently interact with NEMO (Fig. 1A).
Consistent with the idea that SENP2 acts on SUMOylated NEMO upstream of IKK
activation, SENP2 expression also reduced IKK activation (Fig. S2C) and IKK-dependent
phosphorylation of IκBα (Fig. S2D). We conclude that SENP2 can inhibit NF-κB activation
by DNA damage via NEMO deSUMOylation. SENP1 may also induce NEMO
deSUMOylation in vitro but its in vivo effects on NEMO deSUMOylation and NF-κB
response induced by DNA damage are much less efficient than those induced by SENP2.
SENP2 and SENP1 are NF-κB-Inducible Genes
The synthesis of negative regulatory DUBs during cytokine signaling, particularly A20, is
induced by NF-κB to attenuate the NF-κB response (Lee et al., 2000; Wertz et al., 2004;
Sun, 2010). We therefore tested if SENP2 expression could be induced by NF-κB in
response to DNA damage by analyzing the expression of SENP2 (and all other SENP genes)
by qRT-PCR in several cell lines (HEK293, CEM T-cell leukemia, MDA-MB-231 breast
carcinoma) treated with genotoxic agents or TNFα. Significantly, SENP2 was induced by
treatment with VP16 in all cell systems analyzed (Fig. 3A–C, others not shown). SENP1, but
not other SENPs, was also induced by VP16 (Fig. 3A–C). The magnitude of the induction
varied from 3- to >20-fold depending on the cell type. CPT also induced both SENP2 and 1
in HEK293 cells (not shown). Significantly, induction of SENP2 and 1 genes seen in
parental cells was not observed in IκBα-S32/36A expressing cell lines (Fig. 3B–C), in which
IKK-dependent phosphorylation sites of IκBα were mutated causing inhibition of NF-κB
activation and function (Fig. 3D, S3A–B). The increases in SENP2 mRNA were mirrored by
slightly delayed accumulation of SENP2 protein and decreased NF-κB activity in CEM cells
with relatively low basal levels of SENP2 protein (Fig. 3E, S3C). Increased SENP2 levels
correlated with decreased SUMOylated NEMO and resistance to NF-κB activation in
response to a sequential DNA damage challenges induced by CPT and VP16 (Fig. S3D–F).
This was not due to alterations in cell cycle status of the CPT-treated cells since NF-κB
activation by VP16 is not coupled to specific cell cycle phases (Wuerzberger-Davis et al.,
2005). In contrast, TNFα failed to induce SENP2 and SENP1 genes in all cell lines analyzed
(Fig. 3A, others not shown).
SENP2 and SENP1 Genes are Direct NF-κB Targets
To determine if the induction of SENP2 (and SENP1) by NF-κB occurs via a direct
mechanism, we next scanned the presence of putative κB sites in the SENP2/1 loci based on
JASPAR database analysis and identified multiple putative κB elements in the 5′ regions of
both genes (Fig. S4A). To test whether NF-κB directly associated with the SENP2/1 5′
regions, chromatin-immunoprecipitation (ChIP) was performed to measure the occupancy of
p65 (RelA) and the transcriptional coactivator CBP. Both p65 and CBP bound to the
κB-4and -7 regions (κB-7 site had two adjacent sites, termed κB-7.1 and -7.2) located
upstream of the SENP2 start site sequence (Fig. 4A–B) and the κB-6 region (the κB-6 site
had two adjacent sites, κB-6.1 andκB-6.2) in the SENP1 locus (Fig. S4B) in VP16-treated
CEM and HEK293 cells (others not shown). In contrast, p65 failed to bind these sites
following treatment with TNFα (Fig. 4C). EMSA and supershift analyses using
oligonucleotides corresponding to these SENP2 and SENP1 κB sites confirmed their
association with p65 activated by genotoxic signals (Fig. S4C–D).
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To test the functional role of κB sites in the SENP2 promoter/enhancer, we constructed a
luciferase reporter cassette containing a 2.5kb SENP2 upstream region appended 5′ to the
luciferase reporter gene. VP16 exposure of HEK293 cells transfected with this construct
caused a robust induction of the luciferase activity (Fig. 4D). While mutation of the κB-4
site caused a modest reduction in reporter activity, mutations of the κB-7.1 and -7.2 sites
abrogated induction. These results demonstrated that κB-7 sites were the principal functional
NF-κB binding elements for SENP2 induction in response to DNA damage, correlating with
the magnitude of p65 recruitment (Fig. 4B). Interestingly, TNFα exposure that failed to
induce p65 recruitment to the endogenous SENP2 κB sites (Fig. 4B) nevertheless caused
strong induction of the SENP2 5′-luciferase reporter activity (Fig. 4E). These results
demonstrated that the SENP2 locus imposed DNA damage specificity that was lost when 5′
elements were displaced from their endogenous chromatin context.
ATM-Dependent Histone Methylation of SENP2 5′ κB Regions
The above observations suggested the possibility that the SENP2 gene is a “slow” NF-κB
target gene that requires signal-specific chromatin remodeling before NF-κB gains access to
κB sequences (Natoli, 2009). During initiation of transcription, methylation of histone H3
lysine 4 (H3K4) increases the access of the transcription machinery (Cedar and Bergman,
2009; Natoli, 2010). Modulation of the transcriptional repressive marks (e.g., H3K9me2,
H3K27me3) may also accompany transcriptional activation. We evaluated several histone
modifications (H3K4me1, H3K4me2, H3K9me2, H3K27me3) in the SENP2 5′ κB regions
by ChIP analysis before and after DNA damage stimuli. The amount of H3K4me2 spanning
the two critical κB sites in the SENP2 5′ sequence (κB-7 and κB-4 sites) was increased after
VP16 treatment 20–40-fold when corrected for total H3 levels, but not by TNFα exposure
(Fig. 5A, S5A–S5B). Repressive H3K9me2 and H3K27me3 modifications in these regions
were nearly undetectable without stimulation and no changes in their status were seen after
genotoxic insults (not shown). The increase in the level of H3K4me2 over the κB-7 region
was still observed in IκBα-S32/36A expressing HEK293 cells (Fig. 5B). In contrast, the
increase in the level of H3K4me2 across κB-4 region was not observed in IκBα-S32/36A
expressing HEK293 cells (Fig. 5B), indicating that the histone methylation at the major
functional κB-7 region was NF-κB independent but that at the minor κB-4 region was NF-
κB dependent. Preincubation with the ATM inhibitor KU55933 (Fig. 5C) or silencing of
ATM expression by siRNA (Fig. 5D) eliminated the increase in H3K4me2 at both the κB-7
and κB-4 regions with VP16 treatment, showing that ATM was required to increase
modifications at both κB regions. Inhibition of NF-κB by IκBα-S32/36A did not affect ATM
expression (Fig. S5C; De Siervi et al., 2009). Thus, NF-κB-dependent induction of SENP2
involved the ATM-dependent chromatin remodeling of the SENP2 κB regions.
SENP2 Limits Biphasic NEMO SUMOylation and NF-κB Activation
Since our data thus far indicated that SENP2 was the major SUMO protease for NEMO and
an inducible negative regulator of NF-κB activation by DNA damage. SENP2 deficiency
should result in higher and more sustained NF-κB activity. Deficiency of SENP1, a possible
weak secondary inhibitor of NF-κB, may result in a modest activation. To test these
hypotheses, we compared NF-κB activity in wild type (Wt), Senp2−/− (Kang et al., 2010),
and Senp1−/−; (Cheng et al., 2007) MEF cells. In these analyses, we employed CPT since
NF-κB activation by VP16 as measured by EMSA was generally undetectable in these cells
(not shown). Activation of NF-κB by CPT exposure in Wt cells was induced transiently
peaking around 2 h following stimulation (Fig. 6A–B). In Senp2−/− cells, basal activity was
slightly higher and CPT-induced peak activation was ~3-fold higher at 2 h. Interestingly,
CPT induced a second phase of NF-κB activation after 6 h that was not observed in Wt cells.
Re-expression of the SENP2 gene in Senp2−/− MEFs reduced the peak NF-κB activation
observed at 2 h (Fig. S6A). In Senp1−/− cells, both basal and CPT-induced peak NF-κB
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activation was intermediate between Wt and Senp2−/− cells. Importantly, similar to Wt cells,
the second phase of activation was not observed. The lack of the second phase activation in
Wt cells was associated with increased Senp2, but not Senp1, induction (Fig. S6B).
We next assessed whether the increased NF-κB activation in Senp2−/− MEFs was associated
with increased NEMO SUMOylation status. NEMO SUMOylation was transiently induced
at 1 h (Fig. 6C–6D), prior to the peak NF-κB activation seen in these cells (Fig. 6A). NEMO
SUMOylation remained low thereafter in Wt cells. In contrast, in Senp2−/− cells, CPT
exposure induced biphasic NEMO SUMOylation peaking at 2–3 h, followed by a second
peak at 8 h upon prolonged DNA damage stimuli (Fig. 6C–6D), similar to NF-κB activation
seen in these cells (Fig. 6A). Forced expression of SENP2 in Senp2−/− MEFs markedly
reduced our ability to detect NEMO SUMOylation (Fig. S6C) consistent with reduction of
NF-κB activation (Fig. S6A). The total SUMO-1 and SUMO-2/3 modification levels were
higher in Senp2−/− (and Senp1−/−) cells compared to Wt cells (Fig. S6B), similar to
observations made with siRNA analyses (Fig. S1D). IKK kinase assay in CPT-treated Wt
and Senp2−/− cells showed the same trend as that observed for NEMO SUMOylation (Fig.
6F). Thus, the main function of NF-κB-dependent Senp2 induction was to prevent the
second phase of NEMO SUMOylation and IKK and NF-κB activation.
Because NF-κB-dependent induction of IκBα is a well-established mechanism to prevent
NF-κB activation, we next tested the possibility that the biphasic activation of NF-κB could
be uncoupled into separate IκBα- and NEMO SUMOylation-dependent components. To test
this, we next analyzed Nfkbia−/− MEF cells devoid of IκBα. In these MEFs, the drop in NF-
κB DNA binding was not observed following CPT exposure (Fig. 6G) even though IKK
activation was still transient like Wt cells (Fig. 6H). Together, these results indicated that
IκBα ensures the termination of NF-κB activity while the emergence of second wave of
NEMO SUMOylation and IKK activation is prevented by SENP2 in response to chronic
genotoxic stimuli.
SENP2 Suppresses NF-κB-Dependent Cell Survival Responses
To determine the functional significance of NF-κB-dependent SENP2 induction in response
to DNA damage, we examined whether the loss of SENP2, which resulted in biphasic NF-
κB activation (Fig. 6A), impacted cell survival under conditions of genotoxic stress. We
observed cleavage of caspase-3 and PARP-1, markers of apoptosis, occurred later and less
robustly in Senp2−/− cells following CPT exposure compared to Wt cells (Fig. 7A–B). These
results were further confirmed by cell survival assays where Senp2−/− cells were more
resistant to CPT-induced death than Wt cells (Fig. 7C). This resistance in Senp2−/− cells was
NF-κB mediated, since expression of IκBα-S32/36A mutant (Fig. S7A) sensitized them to
Wt levels (Fig. 7C). Moreover, expression of SENP2-wt, but not SENP2-c/s, in Senp2−/−
cells was able to reverse these effects as measured by PARP-1 cleavage (Fig. 7B) and cell
survival assays (Fig. 7D). Finally, knockdown of Senp2 in Wt MEF decreased PARP-1
cleavage (Fig. S7B). Thus, SENP2 deficiency caused NF-κB-dependent resistance to DNA
damage-induced apoptotic cell death. Senp2−/− cells were not intrinsically resistant to
apoptosis as cell death induced by TNFα (+cycloheximide), a treatment that activates a
membrane-initiated cell death pathway, was similar to Wt cells (Fig. S7C). Collectively, our
data support the notion that SENP2 is the primary physiologic SUMO protease for NEMO
and NF-κB-dependent induction of SENP2 prevents the second phase of NF-κB activation
to significantly limit cell survival response to genotoxic stress.
Discussion
In this study, we uncovered SENP2 as the major SUMO protease for NEMO and an
inhibitor of NF-κB activation induced by genotoxic agents. We found that among the six
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human SENPs, SENP2 interacted most efficiently with NEMO and most robustly inhibited
NF-κB activation by DNA damage stimuli. SENP2 overexpression reduced the level of
NEMO SUMOylation and NF-κB activation induced by genotoxic stress. While Wt MEFs
showed transient NF-κB activation, Senp2−/− MEFs showed augmented biphasic genotoxic
stress-induced NEMO SUMOylation and NF-κB activation. This was associated with
increased resistance to cell death induced by genototic stimuli compared to Wt MEFs. All of
these effects in Senp2−/− cells were reversed by SENP2 expression, confirming the
specificity of the SENP2 function. Inhibition of NF-κB activation in Senp2−/− MEFs by
IκBα-S32/36A mutant sensitized them to DNA damage-induced cell death, thus
demonstrating that the changes in cell death response was a consequence of NF-κB
activation. Although mutagenesis and functional reconstitution experiments indicated that
the sites of SUMOylation and subsequent ubiquitination of NEMO following genotoxc
insults are likely the same (Huang et al., 2003), our current data suggest that
deSUMOylation per se is unnecessary for NF-κB activation by DNA damage. The presence
of at least two SUMO and ubiquitin modification sites might allow for signal propagation
without the need for SUMO deconjugation.
Although substrate selection by SUMO-specific proteases may depend on the identity of
SUMO paralogs and subcellular localization, a complete understanding of the mechanisms
by which SENPs select specific substrates is still lacking (Hay, 2007; Mukhopadhyay and
Dasso, 2007; Yeh, 2009). We previously showed that SENP1 could remove SUMO-1 from
NEMO in an in vitro deSUMOylation assay (Mabb et al., 2006), however in vivo, SENP1
failed to efficiently interact with NEMO and mediate SUMO removal from this substrate.
Instead, SENP2 interacted more efficiently with NEMO in vivo and also promoted
deSUMOylation in vitro more efficiently than SENP1 did. A recent proteomic study also
detected a NEMO-SENP2 interaction, although the functional significance of this interaction
was not described (Fenner et al., 2010). Since our data showed that SENP2-NEMO
interactions could occur in the absence of SUMO-1 modification and involved an N-
terminal region of NEMO and a central 200–400 amino acid region of SENP2, SENP2
seems to recognize NEMO via a “docking” mechanism, analogous to certain phosphatases
recognizing their substrates without the need for a phospho-moiety (Bose et al., 2006;
Endicott et al., 1999). However, a SUMO moiety appears to increase the efficiency of
NEMO recognition by SENP2 as a SUMO-1-NEMO fusion protein interacted more
efficiently with SENP2 than unmodified NEMO. Since SENP2 possesses a SUMO-
interacting motif (SIM) adjacent to the C-terminal catalytic domain (Hecker et al., 2006), the
interaction between SUMO-1 and SIM might be involved in further increasing the
specificity of SUMOylated NEMO recognition by SENP2 in vivo.
We also uncovered that SENP2 and SENP1 genes are direct targets of NF-κB specifically
induced by DNA damage. We are unaware of a report that describes direct modulation of
the SUMO pathway components by NF-κB. SENP2 and SENP1 are most closely related to
each other and constitute a sub-group among the human SUMO-specific proteases (Hay,
2007; Mukhopadhyay and Dasso, 2007; Yeh, 2009). Coincidentally, the main NF-κB-p65
binding sites (κB-7.1 and -7.2 for SENP2 and κB-6.1 and -6.2 for SENP1) were also
similarly located in the 5′ regions of these genes. Interestingly, the cytokine TNFα failed to
induce SENP2/1 genes despite its ability to robustly activate NF-κB and induce the SENP2
promoter-luciferase reporter gene when the promoter is taken out of the endogenous
chromatin context. ChIP analysis revealed that VP16, but not TNFα caused H3K4me2
modification at the κB-7 region of SENP2 promoter, a mark associated with transcriptionally
active promoters (Barski et al., 2007; Metzger et al., 2010). This methylation was ATM
dependent but independent of NF-κB activation. Thus, it appears that DNA damage-
activated ATM promoted a chromatin modification of the κB-7 region of the SENP2 gene
by H3K4me2 to potentially permit subsequent NF-κB recruitment for gene transcription.
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This would suggest SENP2 is a “late” NF-κB target gene requiring chromatin remodeling
prior to NF-κB recruitment to κB elements (Natoli, 2009). These findings highlight a role
for ATM in chromatin remodeling by H3K4me2 modification to promote transcription of
specific target genes, though the mechanism remains unclear. A previous study has
described a role for ATM on telomere length regulation with the H3K4 methyltransferase
SpSet1p in S. pombe (Kanoh et al., 2003) and very recent studies indicated the role of ATM
in DNA repair via RNF20 phosphorylation and subsequent regulation in histone
methylation, including H3K4me2 (Moyal et al., 2011; Nakamura et al, 2011). Thus,
additional studies are warranted to define the mechanism behind ATM-mediated H3K4
methylation of SENP2 κB regions and identify other genes that are regulated by a similar
ATM-NF-κB-dependent mechanism.
Based on these findings, we propose the model depicted in Fig. 7E. This model highlights a
conceptual parallel between NF-κB-DUB feedback regulation in cytokine signaling and NF-
κB-SENP feedback regulation in DNA damage signaling. In the former induced by TNFα,
polyubiquitin modification of signaling proteins, including RIP1, is critical for promoting
the formation of signaling complexes to mediate IKK activation (Liu and Chen, 2011).
DUBs, such as A20 and CYLD, can disassemble ubiquitin chains and reduce IKK activation
to limit NF-κB responses. Moreover, the genes encoding these DUBs are transcriptional
targets of NF-κB, thereby establishing a feedback control of IKK activity (Jono et al., 2004;
Lee et al., 2000). NF-κB-dependent induction of IκBα forms the second feedback loop that
directly inhibits NF-κB activity without impacting on IKK activation (Chiao et al., 1994;
Renner and Schmitz, 2009; Sun et al., 1993). In the DNA damage signaling, SUMOylation
of NEMO is a critical signaling event to mediate IKK and NF-κB activation (Huang et al.,
2003; Janssens et al., 2005; Mabb et al., 2006; Stilmann et al., 2009) and the SUMO
protease SENP2 deSUMOylates NEMO to inhibit this pathway. Moreover, transcription of
SENP2 is induced by NF-κB in this signaling context and SENP2 feedback suppresses the
second wave of IKK activation to attenuate NF-κB-dependent cell survival responses.
SENP1 could potentially form a weaker feedback loop since NF-κB can activate SENP1
transcription in different cell types and activation of NF-κB is slightly augmented in
Senp1−/− MEFs following genotoxic stimuli. IκBα is also critical to mediate NF-κB
inhibition without attenuating IKK activation in response to DNA damage. As in the case
with DUBs in the cytokine signaling (Sun, 2010), the relative significance of NF-κB-
dependent feedback regulation mediated by SENPs in genotoxic signaling probably depends
on cell types and the nature of DNA damage stimuli, as different cell types display varying
propensities to induce these SUMO proteases. This mechanism of DNA damage sensitivity
induced by NF-κB-dependent induction of SENP2 contrasts with a recently described NF-
κB-dependent pro-cell death mechanism in response to excessive amounts of DNA damage
involving a second phase of NF-κB activation mediated by autocrine production of TNFα to
induce RIP1-FADD-caspase 8-dependent cell death (Biton and Ashkenazi, 2011). Defining
how the magnitude of DNA damage in the nucleus is molecularly decoded to drive NF-κB-
mediated cell survival or death responses awaits further investigation.
Stress-induced NF-κB activation that in turn induces SENP2/1 synthesis provides a unique
temporal mechanism to coordinate the sumoylation-desumoylation cycle in response to
genotoxic stress conditions. Is NF-κB signaling the only process that is modulated by the
NF-κB-SENP2/1 pathway induced by DNA damage? Recent studies revealed that SUMO
proteins, the SUMO conjugating enzyme UBC9, and SUMO ligases PIAS1 and PIAS4
(PIASy) are recruited to the DNA damage site and mediate SUMOylation of key DNA
damage response proteins, including BRCA1 and 53BP1 (Galanty et al., 2009; Morris et al.,
2009). SUMOylation of BRCA1 and 53BP1 is required for accumulation of ubiquitinated
histone H2A and H2AX at the damage sites and is required for efficient DNA repair. Thus,
it is plausible that NF-κB-induced SENP2/1 may also regulate other DNA damage response
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components, such as BRCA1 and 53BP1 whose deSUMOylation mechanisms are currently
undefined. In this manner, NF-κB-dependent SENP2/1 induction could provide a delayed
timing mechanism to deSUMOylate multiple proteins at DNA damage sites to help resolve
or reset the DNA damage response. As the DNA damage response is critical for genome
integrity and susceptibility to cancer (Jackson and Bartek, 2009; Stracker et al., 2009),
identification of other SUMO targets that are regulated by this NF-κB-SENP2/1 axis in
response to genotoxic agents may shed additional light on the expanding role of NF-κB in
promoting oncogenesis and cancer resistance (Grivennikov et al, 2010).
Experimental Procedures
For further details see Supplemental Information.
Cells, antibodies, and reagents
HEK293 cells, those stably expressing Myc-NEMO or HA-IκBα-S32/36A, and Wt,
Senp1−/− and Senp2−/− MEF cells were grown at 37°C in DMEM supplemented with 100
units/mlof penicillin, 1 μg/mlof streptomycin, and 10% fetal bovine serum (FBS). MDA-
MB-231, CEM, and those stably expressing HA-IκBα-S32/36A were grown at 37°C in
RPMI-medium supplemented as above. Antibodies against Myc (9E10), NEMO (FL-419),
IKKα/β (H-470), IκBα (C-21), SENP2 (H-300), p65 (C-20), and CBP (A-22) were
purchased from Santa Cruz (CA). Antibodies against tubulin, caspase3, and PARP-1
(Calbiochem, CA), SUMO-1 (GMP1) and SUMO-2 (Invitrogen, CA), NEMO (BD
pharmingen, CA), Flag M2 (Sigma, MO), HA (Roche), phospho-S32/S36-IκBα (Cell
Signaling), and H3, H3K4me, H3K4m2, H3K9me2 and H3K27me3 (Fishers) were also
used. VP16 (10 μM), TNFα (10 ng/ml), CPT (10 μM) and KU55933 (10 μM) were used
unless otherwise noted.
HEK293 cells were transiently transfected by a standard Ca2+ -phosphate method. Senp2−/−
MEF cells were electroporated with pQCXIP-3Flag-SENP2 or empty vector and were
selected with puromycin (4 μg/ml) to generate pools of stable cells. Transient transfection
was performed similarly without the selection with puromycin.
Quantitative RT-PCR
Total RNAs were prepared by RNeasy miniprep kit (Qiagen). cDNAs were synthesized by
reverse-transcriptase. Quantitative RT-PCR was performed with appropriate primers and
analyzed using Bio-Rad iQ5 system. The primers are shown in Supplementary information.
All experiments were done in triplicates for three independent times.
ChIP assay
2×106 CEM or HEK293 cells were treated with VP16 or TNFα for 3 h. Cells were then
processed as previously described (Wu and Miyamoto, 2008). Briefly, one μg of p65, CBP,
H3K4me2, or rabbit IgG antibody was used. DNA-protein complexes were eluted in 150 μL
of elution buffer (1% SDS, 0.1 M NaHCO3) for 15 min, twice. DNA-protein cross-links
were reversed by incubation at 65°C for overnight. Following treatment with proteinase K,
DNA was extracted by Qiagen miniprep kit. Primer pairs used to amplify a specific region
of SENP2 and SENP1 promoters and all others primers used are listed in Supplementary
Information. All analyses were done in triplicates in three independent experiments.
Cell viability assay
5×103 cells were seeded on a 6-well plate and cultured for 5 days with or without various
doses of CPT. After 5 days, cells were washed with PBS and stained with 0.5% crystal
violet solution for 20 min. These cells were then washed with water and dried. To analyze
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survival rates, methanol was added to each stained well and the resulting dye signals were
read on a spectrophotometer (OD540). All experiments were done in duplicate for three
independent times.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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SENP2 associates with NEMO and negatively regulates NF-κB activation by genotoxic
stress. (A) Flag-SENP1, 2, 3, 5, 6, and 7 were co-transfected with Myc-NEMO in HEK293
cells. Transfected cells were treated with 10 μM VP16 for 1 h, lysed and NEMO was then
precipitated with Myc antibody and analyzed by immunoblot using Flag or NEMO antibody.
(B) HEK293 cells were transfected with vector (−) or SENP constructs and treated as above.
Lysates were used for EMSA using a radio-labeled Igκ-κB or Oct-1 probe. (C)
Phosphorimage quantified results from four experiments as in (B) were plotted (mean
+SEM). *, p<0.03. (D) HEK293 cells were transfected with varying amounts of Flag-
SENP2 wild type (wt) or a catalytically inactive mutant (c/s) and were analyzed by EMSA
as in (A). (E) HEK293 cells were co-transfected with SENP2-wt, -c/s, or -siRNA
(SMARTpool, Dharmacon) and 3x-κB-luciferase and β-galactosidase constructs. Twenty-
four hours following transfection, cells were treated with VP16 or DMSO for 8 h and
extracts were analyzed by immunoblotting using SENP2 or tubulin antibody. (F) Cell
samples as in (E) were analyzed for luciferase and β-galactosidase activities and relative
luciferase activity was plotted (mean+SEM). *, p<0.03; **, p<0.001. See also Figure S1.
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SENP2 binds to NEMO and promotes NEMO deSUMOylation. (A) HEK293 cells stably
expressing 6xMyc-NEMO were transfected with Flag-SENP2-wt or -c/s constructs, treated
with VP16 (1 h) at 24 h after transfection, and then lysed in 1% SDS lysis buffer. Cell
lysates were immediately boiled and then SDS diluted to 0.1% final with IP buffer before
NEMO was precipitated using Myc antibody for subsequent immunoblot analysis using Myc
or SUMO1 antibody. SUMOylated NEMO is indicated by S~NEMO. (*) indicates the IgG
heavy chain. (B) HEK293 cells were treated as indicated and used for NEMO IP followed
by immunoblot using SENP2, IKKα/β, or NEMO antibody. (C) HEK293 cells were
cotransfected with Flag-SENP2-cs and Myc-NEMO truncation constructs (N1–4) and used
for Myc IP followed by Flag or Myc immunoblot. Binding data (Bd) data are summarized
with diagrams of mutants. (D) HEK293 cells were transfected with Myc-NEMO and Flag-
SENP2 truncation constructs (S1–S5) and used for Flag IP followed by Myc or Flag
immunoblot. Binding (Bd) data are summarized as above with S (*) indicating SUMO-
interaction motif (SIM) and C (#) the catalytic site. (E) HEK293 cells were co-transfected
with Myc-NEMO or SUMO-1 (minus the C-terminal di-glycine motif) fused NEMO (S1-
NEMO) and Flag-SENP2 and used for Myc IP followed by immunoblotting using indicated
antibodies. (F) HEK293 cells were transfected with varying amounts of Flag-SENP1-wt or
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Flag-SENP2-wt constructs, treated with VP16 for 1 h and used for Flag IP. SUMOylated
NEMO (S~NEMO) was prepared using in vitro translation and SUMOylation assay (Mabb
et al. 2006). SUMOylated NEMO was incubated with Flag-purified SENP1 or SENP2 for 2
h at 37°C and analyzed by NEMO or Flag immunoblotting. Lower graph: the percentages of
SUMOylated NEMO amounts remaining with increasing amounts of transfected SENP
constructs are indicated (mean+SD) from two experiments. See also Figure S2.
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SENP2 and SENP1 genes are NF-κB-regulated genes selectively induced in response to
genotoxic stress. (A) HEK293 cells treated as indicated were analyzed for SENP2 mRNA
expression by qRT-PCR and graphed (mean+SEM). (B, C) Indicated parental and those
stably expressing HA-IκBα-S32/36A were treated with VP16 for indicated times and
analyzed as in (A) for SENP2 (B) or SENP1 mRNA (C) expression. The difference
compared to untreated samples in parental cells; *, p<0.05; **, p<0.02; #, p<0.001. (D, E)
CEM cells and those stably expressing HA-IκBα-S32/36A were treated as indicated and
analyzed by EMSA (D) or immunobloting using indicated antibodies (E). See also Figure
S3.
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SENP2 is a direct NF-κB target gene. (A) A diagram showing putative κB binding sites in
the 5′ region of the SENP2 locus. (B) CEM cells were incubated with VP16 for 3 h and then
subjected to ChIP analysis using IgG, p65, or CBP antibodies and qPCR using primers
(Supplement Information) spanning each of the putative κB binding sites (indicated with
numbers). % input over total qPCR signals for each antibody is shown (mean+SEM). (C)
Similar analyses as in (B) were done except for treating cells with TNFα for 3 h. (D)
HEK293 cells were transfected with an empty luciferase reporter construct (CTL), SENP2 5′
sequence-luc (−2520), or SENP2 5′ sequence-luc with the κB sites mutated (indicated by
“X”), along with β-galactosidase control vector, and treated with VP16 for 10 h. Luciferase
activity corrected for β-galactosidase activity was plotted as fold luciferase activity (mean
+SEM). *, p<0.001. (E) Similar analyses as in (D) were performed except for exposure of
cells to TNFα for times indicated. See also Figure S4.
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ATM-regulated histone methylation of SENP2 promoter in response to DNA damage. (A)
HEK293 cells were incubated with TNFα (T) or VP16 (V) for 3 h. ChIP was performed
using H3K4me2 or IgG control antibody and analyzed by qPCR with specific primers
around the indicated SENP2 κB sites. The data are displayed as in Fig. 4B (mean+SEM). *,
p<0.01. **, p<0.001. (B) HEK293 cells stably expressing HA-IκBα-S32/36A were analyzed
as in (A). **, p<0.001. n.s., not significant. (C) HEK293 cells pretreated with KU55933 for
1 h followed by TNFα (T) or VP16 (V) for 3 h were analyzed as in (A). (D) HEK293 cells
were transfected with control or ATM-targeting siRNA and then treated with VP16 (V) for 3
h prior to ChIP analysis using antibodies indicated. The efficiency of ATM knockdown was
also evaluated by immunoblotting with ATM antibody. See also Figure S5.
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SENP2 is required to attenuate a biphasic NEMO SUMOylation and NF-κB activation in
response to DNA damage. (A) Different MEFs treated as indicated were analyzed by
EMSA. (B) Phosphorimage quantification of NF-κB/AP1 binding from three independent
experiments as in (A) was plotted (mean+SD). *p<0.001. **, p<0.01. (C) Different MEFs
treated as indicated were processed as in Fig. 2A and SUMOylated NEMO (S~NEMO) was
detected by immunoblotting with SUMO1 antibody (upper). (D) S~NEMO signals from (C)
from two experiments were quantified by ImageJ analysis of scanned blots and plotted with
the mean+SD for each time point indicated. (E) IKK immune-complex kinase assay was
performed using GST-IκBα(1–56) as substrate. The amounts of the substrate and NEMO
used for IKK immunoprecipitation are shown by immunoblotting. (F) NF-κB activation in
Wt and Nfkbia−/− MEFs were analyzed as in (A). (G) IKK kinase assay was performed using
Nfkbia−/− MEF as in (E). See also Figure S6.
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SENP2 is required to limit NF-κB-dependent cell survival in response to DNA damage. (A)
Wt and Senp2−/− MEFs treated as indicated were analyzed by immunoblotting with
indicated antibodies. (B) Senp2−/− MEFs stably reconstituted with SENP2-wt, SENP2-c/s or
vector control (Vec) were analyzed as in (A). (C) Wt, Senp2−/− and Senp2−/− stably
expressing HA-IκBα-S32/36A (Senp2−/−S32/36A) were exposed to different doses of CPT
and cell viability was analyzed as in ‘Experimental Procedures’ and plotted (mean+SEM).
(D) MEF cells as in (B) were analyzed as in (C). *, p<0.01. **, p<0.001. (E) A model
depicting negative feedback regulation of NF-κB signaling induced by TNFα or DNA
damage. See Discussion for details. See also Figure S7.
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